Skip to main content

United States News All stories

Every story in this section, newest first — page 207 of 373.

Grafa

Regeneron revenue surges 19% as EYLEA HD momentum and global Dupixent sales offset manufacturing headwinds

Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong financial results for the first quarter of 2026 on Wednesday, April 29, 2026, highlighted by high-double-digit revenue growth and significant regulatory milestones.

Read more: Regeneron revenue surges 19% as EYLEA HD momentum and global Dupixent sales offset manufacturing headwinds
Grafa
Technology

Cognizant revenue hits $5.4B as new ‘project leap’ efficiency drive targets $300M in savings

Cognizant Technology Solutions (NASDAQ:CTSH) announced its financial results for the first quarter ended March 31, 2026, on Wednesday, April 29, 2026, delivering top-line growth and a significant increase in profitability.

Read more: Cognizant revenue hits $5.4B as new ‘project leap’ efficiency drive targets $300M in savings
Grafa

GE HealthCare revenue rallies 7% despite supplier disruptions and inflationary headwinds

GE HealthCare Technologies (NASDAQ:GEHC) reported financial results for the first quarter ended March 31, 2026, revealing a complex landscape of steady demand offset by operational hurdles and macroeconomic pressures.

Read more: GE HealthCare revenue rallies 7% despite supplier disruptions and inflationary headwinds
Grafa
Technology

Avantor revenue holds steady at $1.58B as high-margin segments support margins

Avantor (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, reported financial results for the first quarter ended March 31, 2026.

Read more: Avantor revenue holds steady at $1.58B as high-margin segments support margins
Grafa

Henlius and Organon secure EC approval for POHERDY, Europe’s first Pertuzumab biosimilar

Shanghai Henlius Biotech and Organon (NYSE:OGN) announced on Wednesday, April 29, 2026, that the European Commission (EC) has granted marketing authorization for POHERDY (pertuzumab), making it the first and only approved biosimilar to the reference product PERJETA in Europe.

Read more: Henlius and Organon secure EC approval for POHERDY, Europe’s first Pertuzumab biosimilar
Grafa
Auto and cars

PACCAR Q1 profit jumps to $605M as parts and financial services drive results

PACCAR (NASDAQ:PCAR) reported solid financial results for the first quarter of 2026, marked by a sharp increase in net income and a growing production backlog that signals robust demand for its Kenworth, Peterbilt, and DAF truck brands.

Read more: PACCAR Q1 profit jumps to $605M as parts and financial services drive results